BNP Paribas Arbitrage SA lifted its holdings in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 70.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,904 shares of the biopharmaceutical company’s stock after purchasing an additional 9,847 shares during the quarter. BNP Paribas Arbitrage SA owned 0.05% of Acorda Therapeutics worth $565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. State of Wisconsin Investment Board bought a new stake in shares of Acorda Therapeutics in the second quarter worth $630,000. Dimensional Fund Advisors LP grew its holdings in shares of Acorda Therapeutics by 29.6% in the second quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock worth $46,745,000 after acquiring an additional 541,418 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Acorda Therapeutics by 306.8% in the second quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock worth $10,538,000 after acquiring an additional 403,467 shares during the period. Teachers Advisors LLC grew its holdings in shares of Acorda Therapeutics by 8.0% in the second quarter. Teachers Advisors LLC now owns 78,886 shares of the biopharmaceutical company’s stock worth $1,554,000 after acquiring an additional 5,837 shares during the period. Finally, State Street Corp grew its holdings in shares of Acorda Therapeutics by 52.4% in the second quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after acquiring an additional 851,290 shares during the period.

In other news, insider Burkhard Blank sold 11,050 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the sale, the insider now directly owns 33,150 shares in the company, valued at $680,569.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 7.90% of the company’s stock.

ACOR has been the subject of several recent research reports. Cowen reissued a “buy” rating and set a $35.00 price target on shares of Acorda Therapeutics in a report on Tuesday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 price objective (down previously from $30.00) on shares of Acorda Therapeutics in a research note on Thursday, August 31st. HC Wainwright began coverage on Acorda Therapeutics in a research report on Wednesday, November 8th. They issued a “buy” rating and a $35.00 target price on the stock. TheStreet downgraded Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, November 17th. Finally, J P Morgan Chase & Co set a $24.00 target price on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, October 31st. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $21.47.

Shares of Acorda Therapeutics, Inc. (NASDAQ ACOR) opened at $20.75 on Friday. Acorda Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $33.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The business had revenue of $141.07 million during the quarter, compared to analysts’ expectations of $150.64 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. analysts predict that Acorda Therapeutics, Inc. will post -0.07 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Acorda Therapeutics, Inc. (ACOR) Stake Lifted by BNP Paribas Arbitrage SA” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/12/08/acorda-therapeutics-inc-acor-stake-lifted-by-bnp-paribas-arbitrage-sa.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.